ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

オキシフェンブタゾン

Oxazolidin

HCID 4641
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
129-20-4
標準SMILES
CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
分子式
C19H20N2O3
平均分子量
324.4 g/mol
単同位体質量
324.1473925

概要

Oxyphenbutazone is a metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. It has a role as an antimicrobial agent, a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, an antineoplastic agent, a gout suppressant, a drug metabolite and a xenobiotic metabolite. It is a member of phenols and a member of pyrazolidines. It is functionally related to a phenylbutazone.

名称と識別子

優先名称
Oxazolidin
IUPAC
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
現地名
オキシフェンブタゾン
英語名
Oxyphenyl butazone
分子式
C19H20N2O3
分子量
324.37

名称と別名

oxyphenbutazone129-20-4OxyphenylbutazoneTandearilFlogitoloFlogorilFrabelOxalidNeo-FarmadolCrovarilOxazolidinVisubutina
名称をさらに表示
1-フェニル-2-(p-ヒドロキシフェニル)-3,5-ジオキソ-4-ブチルイソピラゾリジンビスブチナフロギトロ4-ブチル-2-(4-ヒドロキシフェニル)-1-フェニルピラゾリジン-3,5-ジオンオキシフェンブタゾンネオファルマドール4-ブチル-2-(4-ヒドロキシフェニル)-1-フェニル-3,5-ピラゾリジンジオン4-ブチル-1-(p-ヒドロキシフェニル)-2-フェニルピラゾリジン-3,5-ジオンフラベルタンデアリルp-ヒドロキシフェニルブタゾン4-ブチル-1-(4-ヒドロキシフェニル)-2-フェニルピラゾリジン-3,5-ジオンフロゴリルオキシフェニルブタゾングロバリルオキサリドタンダコートタンデリル4-ブチル-1-(4-ヒドロキシフェニル)-2-フェニル-3,5-ピラゾリジンジオンbm1BM 1Flogalg27202IridilMysiteNeofen
OxifenylbutazonOxiphenbutazoneButapironeCalifornitTandacoteFlamarilOxyphenobutazonep-Oxyphenylbutazone

物性

構造計算による物性

XLogP
2.7
極性表面積
60.9 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
5
重原子数
24
形式電荷
0
複雑度
454

実験および物理化学的性質

LogP3.04
OdorODORLESS
Color/FormWHITE TO YELLOWISH WHITE, CRYSTALLINE POWDER
Solubility · 2 件

ANHYDROUS CRYSTALS FROM ETHER & PETROLEUM ETHER WITH MP 124-125 °C; ACIDIC REACTION; MP 96 °C; FORMS WATER-SOL SODIUM SALT; SOL IN ETHANOL, METHANOL, CHLOROFORM, BENZENE, ETHER /MONOHYDRATE/

VERY SLIGHTLY SOL IN WATER; FREELY SOL IN ACETONE

Human Drugs · 3 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Collision Cross Section · 3 件

163.33 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

177.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

184.74 Ų [M-H]-

物理化学的性質

融点
109 · 109-111°C
沸点
462.71 °C · 462.71°C (rough estimate)
比重(密度)
1.2118 · 1.2118 (rough estimate)
屈折率
1.614 · 1.6140 (estimate)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Interactions · 5 件

SOME TRICYCLIC COMPD HAVE BEEN SHOWN TO DELAY OXYPHENYLBUTAZONE ABSORPTION IN RAT BY INCR GASTRIC EMPTYING TIME.

...OXYPHENBUTAZONE MAY PROLONG PROTHROMBIN TIME IN PT RECEIVING COUMARIN ANTICOAGULANTS CONCOMITANTLY & MAY INCR HYPOGLYCEMIC EFFECT OF INSULIN & ORAL HYPOGLYCEMIC AGENTS.

WHEN OXYPHENBUTAZONE & METHANDROSTENOLONE ARE ADMIN CONCURRENTLY IN HUMANS, SERUM OXYPHENBUTAZONE LEVELS MAY BE ELEVATED. PT TREATED WITH THESE CONCURRENTLY SHOULD BE MONITORED FOR SIGNS OF OXYPHENBUTAZONE-INDUCED ADVERSE EFFECTS.

OXYPHENBUTAZONE ABSORPTION...IS DECR BY DESIPRAMINE.

For more Interactions (Complete) data for OXYPHENBUTAZONE (6 total), please visit the HSDB record page.

Human Toxicity Excerpts · 5 件

NAUSEA, VOMITING, EPIGASTRIC DISCOMFORT, & SKIN RASHES ARE MOST FREQUENTLY REPORTED UNTOWARD EFFECTS. DIARRHEA, VERTIGO, INSOMNIA, EUPHORIA, NERVOUSNESS, HEMATURIA...& BLURRED VISION HAVE ALSO BEEN OBSERVED. ...WATER & ELECTROLYTE RETENTION & EDEMA FORMATION OCCUR. /PHENYLBUTAZONE/

化学と産業

薬理情報

ATC Code · 6 件

S - Sensory organs

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QS - Sensory organs

QM - Musculo-skeletal system

Mechanism of Action · 1 件

...HAS PROMINENT ANTI-INFLAMMATORY EFFECTS IN ANIMALS, & COMPARABLE EFFECTS... IN PT WITH RHEUMATOID ARTHRITIS & RELATED DISORDERS. ...INHIBITS BIOSYNTHESIS OF PROSTAGLANDINS, UNCOUPLES OXIDATIVE PHOSPHORYLATION, & INHIBITS ATP-DEPENDENT BIOSYNTHESIS OF MUCOPOLYSACCHARIDE SULFATES IN CARTILAGE. /PHENYLBUTAZONE/

Biological Half-LifeIN MAN, OXYPHENBUTAZONE HAS BIOLOGICAL HALF-LIFE OF ABOUT 2 DAYS.
Metabolism/MetabolitesOXIDN OF PHENYLBUTAZONE DURING CHRONIC DOSING BY MEASURING URINARY EXCRETION OF 3 METABOLITES, OXYPHENBUTAZONE GAMMA-HYDROXYPHENBUTAZONE & P,GAMMA-HYDROXYPHENBUTAZONE DURING INFUSION OF HYDROCORTISONE SODIUM SUCCINATE IS REPORTED.
MeSH Pharmacological Classification · 1 件

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Absorption, Distribution and Excretion · 1 件

...OXYPHENBUTAZONE IS EXTENSIVELY BOUND TO PLASMA PROTEINS & HAS PLASMA HALF-TIME OF SEVERAL DAYS. ...ONLY SLOWLY EXCRETED IN URINE, SINCE BINDING TO PLASMA PROTEIN LIMITS...GLOMERULAR FILTRATION, &...RELATIVELY HIGH PKA, WHICH FAVORS PASSIVE REABSORPTION IN DISTAL TUBULE.

用途と製造

関連反応

5 件
反応記録を作成
HRID 259177 の反応式
HRID 259177反応物として
HRID 1076799 の反応式
HRID 1076799反応物として
HRID 1390723 の反応式
HRID 1390723反応物として
HRID 1764768 の反応式
HRID 1764768反応物として
HRID 1863518 の反応式
HRID 1863518反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
129-20-4、7081-38-1
PubChem CID
4641
DTXSID
DTXSID1045291
ChEMBL
CHEMBL1228、CHEMBL3989676
ChEBI
CHEBI:76258
UNII
A7D84513GV
EC Number
204-936-2
Nikkaji
J10.648H
貯蔵温度
-20 °C · -20°C
溶解性
10 mg/mL、透明 · DMSO:可溶10mg/mL、透明
酸解離定数(Pka)
4.7 · pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
外見
粉
色
白から茶色
水溶解度
20 mg/L · 20mg/L(室温)
安定性
Hygroscopic
InChI
1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
SMILES
N2(N(C(=O)C(C2=O)CCCC)c3ccccc3)c1ccc(cc1)O
CAS データベース
129 · 129-20-4(CAS DataBase Reference)
EPAの化学物質情報
3 · 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4)

化学的性質

化学的特性Light Beige Solid

MORE SERIOUS FORMS OF ADVERSE EFFECTS INCL PEPTIC ULCER...WITH HEMORRHAGE OR PERFORATION, HYPERSENSITIVITY REACTIONS OF SERUM-SICKNESS TYPE, ULCERATIVE STOMATITIS, HEPATITIS, NEPHRITIS, APLASTIC ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA. NUMBER OF DEATHS HAVE OCCURRED... /PHENYLBUTAZONE/

...32-YR OLD WOMAN WHO WAS TREATED WITH 2.5 G OXYPHENBUTAZONE OVER 7 DAYS; SHE...DEVELOPED SEVERE LEUCOCYTOSIS FOLLOWED BY LEUCOPENIA & ANEMIA...SUBSEQUENT RECOVERY.

ADMIN OF PHENYLBUTAZONE...IS ASSOC WITH...BONE MARROW SUPPRESSION. TOXICITY OF OXYPHENBUTAZONE IS SIMILAR TO THAT OF PARENT COMPD... /PHENYLBUTAZONE/

NUMBER OF CASES OF LEUKEMIA WERE REPORTED BETWEEN 1960 & 1966 IN SUBJECTS TREATED WITH PHENYLBUTAZONE OR OXYPHENBUTAZONE. AVAIL EVIDENCE IS, HOWEVER, INSUFFICIENT TO SUBSTANTIATE SUGGESTION THAT USE...IS RELATED TO SUBSEQUENT DEVELOPMENT OF LEUKEMIA.

Carcinogen Classification · 5 件

Oxyphenbutazone

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 13: (1977) Some Miscellaneous Pharmaceutical Substances

1987

1987

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Oxyphenbutazone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 件

.../PHENYLBUTAZONE/ DID NOT INDUCE NON-DISJUNCTION OR CROSSING-OVER IN ASPERGILLUS NIDULANS IN ABSENCE OF METABOLIC ACTIVATION, WHEREAS ITS METABOLITE, OXYPHENBUTAZONE, HAD WEAK BUT SIGNIFICANT ACTIVITY.

GASTRIC ULCERATIONS WERE PRODUCED IN DOGS AFTER PROLONGED IM ADMIN OF DOSES OF 3.6-35.2 G PHENYLBUTAZONE OVER 10-103 DAYS. /PHENYLBUTAZONE/

Evidence for CarcinogenicityNo data are available in humans. No data are available in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.

安全データ

wgk
3
ridadr
UN 3077 9 / PGIII
hs_code
2933990099
risk_code
22-50
hazard_code
Xn,N
safety_code
61
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1
ストレージクラス
11 - Combustible Solids
有毒物質データの
129-20-4(Hazardous Substances Data)
Uses · 2 件

MEDICATION

MEDICATION (VET)

Methods of ManufacturingHAFLIGER, US PATENT 2,745,783 (1956 TO GEIGY): PFISTER, HAFLIGER, HELV CHIM ACTA 40, 395 (1957).
Formulations/PreparationsOXYPHENBUTAZONE, NF (TANDEARIL), IS MARKETED IN 100-MG TABLETS.
Use ClassificationPharmaceuticals
General Manufacturing Information · 1 件

OXYPHENBUTAZONE IS HYDROXY ANALOG OF PHENYLBUTAZONE & ONE OF MAJOR ACTIVE METABOLITES OF PARENT DRUG. ... OXYPHENBUTAZONE HAS SAME SPECTRUM OF ACTIVITY, THERAPEUTIC USES, INTERACTIONS, & TOXICITY AS PARENT COMPD, & IT SHARES SAME INDICATIONS, DANGERS, & CONTRAINDICATIONS FOR CLINICAL USE.

応用分野 · 2 件

使用Anti-inflammatory;Cyclooxygenase inhibito

一般的な説明Oxyphenbutazone is a derivative compound of phenylbutazone. Oxyphenbutazone is one of the metabolites formed in the liver following administration of phenylbutazone. Given orally it causes fewer gastrointestinal adverse effects than phenylbutazone and is used at 300 – 400 mg/d for the same indications as the parent drug.

上流・下流製品情報

上流原料

1-フェニル-2-[4-(フェニルメトキシ)フェニル]ヒドラジン水素ナトリウム
補足説明 · 1 件

定義ChEBI: A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following asso iation with blood dyscrasis and Stevens-Johnson syndrome.